乳腺癌的延长内分泌治疗

Extended endocrine therapy of breast cancer

内分泌治疗是雌激素受体（ER）阳性乳腺癌治疗的重要手段之一，乳腺癌5年辅助内分泌治疗后远期复发却很常见。延长内分泌治疗（EET）是一种很有前景的策略，可进一步降低复发的风险、增加早期患者的治愈机会。EET决策需权衡远期复发风险、月经状态、不良反应及患者意愿，从而个体化实施。未来研究仍需探索哪些患者能从EET中最大获益。

Endocrine therapy is an important treatment of estrogen receptor （ER） positive breast cancer. However, late relapse after completion of 5-year adjuvant endocrine therapy is still common. Extended endocrine therapy （EET） is a promising strategy to further reduce the risk of recurrence and increase the cure rate in early-stage patients. The decision-making to EET should be individually implemented by weighing the risk of late recurrence, menopausal status, side effects, and patients＇ preference. Future studies are still nee- ded to identify the patients who are most likely to benefit from EET.